Vulvodynia is a condition characterized by pain around the vaginal opening. The impact of this condition on a woman's life can be profound, affecting sexual relationships, daily activities, overall well-being, and quality of life. The prevalence of vestibulitis varies across studies, but findings suggest it affects between 10 percent and 20 percent of women aged 18 to 29 years.

VagiVital Intimate Calming Gel provides immediate relief from vaginal irritation, dryness, itching, burning sensations, or pain during intimate intercourse. These symptoms can result from various causes, such as tight clothing, hygiene products, sanitary pads, or provoked vulvodynia. The product is based on the Company's proven gel formulation, AktivGel, which is renowned for its documented moisturizing properties. VagiVital Intimate Calming Gel is intended for use on the external intimate area. For more persistent symptoms, combining the product with VagiVital AktivGel is recommended for deep intravaginal moisturization.

"The U.S. patent, which complements our previous European approval, is strategically important for protecting our product, VagiVital Intimate Calming Gel. The product is a key part of our growth strategy in the U.S. market, where it is planned to become available to consumers in March," says Anna Linton, CEO of Peptonic Medical.

For further information, please contact:                                                                                                       
Anna Linton, CEO Peptonic Medical AB                                                                                                                  
Email: anna.linton@peptonicmedical.se                                                                                                                 
Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                              

PEPTONIC medical AB (publ) is a pioneering Swedish medical device company, focused on the development and sale of clinically proven self-care treatments and self-diagnostic tests in the field of women's intimate health. The product portfolio is marketed under the brands VagiVital and Vernivia. The company aim to revolutionize intimate self-care by providing women a unique comprehensive solution to independently diagnose, treat, and prevent medical conditions in the intimate area. A key pillar of Peptonic's growth strategy is the geographic expansion of VagiVital and Vernivia in the U.S. and Europe. The company also seeks to continuously expand its product portfolio through acquisitions and in-house product development.

Peptonic Medical is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc, in the U.S. Founded in 2009, Peptonic Medical has been listed on the Spotlight Stock Market since 2014.